Arrowhead Pharmaceuticals Inc

ARWR has delivered a clear momentum breakout above the ~77 resistance on heavy volume, signaling a new expansionary phase, but price is currently stretched above rising EMAs and in extreme overbought territory. Medium-term bias remains bullish in Stage 2 with HH/HL structure intact. Execution is best deferred until a pullback into the 77–79 support zone near the 9/20 EMAs for better risk–reward.

• ↑Q3 revenue $75.3M beat forecasts; net loss was $194.3M
• ↑Phase 3 SHASTA-3/4 trials achieved 79–81% triglyceride cuts, fewer pancreatitis events
• ↓Q3 net loss $194.3M and EPS $1.36 miss underscore high expenses